Ikeda H, Nagashima K, Okumura H, Takahashi A, Matsuyama S, Nagamachi Y
First Department of Surgery, Gunma University School of Medicine, Japan.
Eur J Surg Oncol. 1988 Feb;14(1):17-20.
Urinary excretion of beta 2-microglobulin and N-acetyl-beta-D-glucosaminidase (NAG) were determined in eight patients with advanced neuroblastoma receiving cis-diamminedichloroplatinum(II) (CDDP). Urinary excretion of beta 2-microglobulin was increased within 3 days after CDDP treatment and returned to its pretreatment level within the first week. Increased urinary excretion of NAG was observed until the end of the second week after CDDP administration. But the measured values on the third day after CDDP administration were not significantly correlated with the accumulated dose of CDDP administered. These results indicate that beta 2-microglobulin excretion and NAG enzymuria after CDDP treatment are sensitive parameters of acute renal tubular damage, but the long-term latent nephrotoxicity of CDDP cannot be predicted from these parameters.
对8例接受顺二氯二氨铂(II)(CDDP)治疗的晚期神经母细胞瘤患者测定了β2-微球蛋白和N-乙酰-β-D-氨基葡萄糖苷酶(NAG)的尿排泄情况。CDDP治疗后3天内β2-微球蛋白的尿排泄量增加,并在第一周内恢复到治疗前水平。在CDDP给药后第二周结束前均观察到NAG尿排泄量增加。但CDDP给药后第三天的测量值与所给予的CDDP累积剂量无显著相关性。这些结果表明,CDDP治疗后的β2-微球蛋白排泄和NAG酶尿是急性肾小管损伤的敏感参数,但无法从这些参数预测CDDP的长期潜在肾毒性。